The purpose of this study is to obtain information on the efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The sponsor is Chiesi Farmaceutici.
Criteria:
Minimum:
Males and females aged 40 years with written informed consent obtained prior to any study-related procedure.
Subjects with an established diagnosis of COPD
Current smokers or ex-smokers who quit smoking at least 6
months prior to screening visit,